A Niwińska1, K Pogoda, M Murawska, P Niwiński. 1. Breast Cancer and Reconstructive Surgery Department, The Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5 Str 02-781, Warsaw, Poland. alphaonetau@poczta.onet.pl
Abstract
AIM: To perform a comprehensive analysis of patients with breast cancer and solitary or single brain metastasis and to analyze factors influencing survival from brain metastasis. METHODS: One hundred consecutive patients with single or solitary brain metastasis were treated in one institution in the years 2003-2009. Brain lesions were diagnosed by magnetic resonance imaging (MRI). A total of 57% of patients underwent resection of brain metastasis, 95% of patients received whole-brain radiation therapy (WBRT) and 67% were treated systemically after WBRT. RESULTS: Median survival from the detection of brain metastasis was 13 months and 28% of patients survived for 2 years. In 29 patients with solitary brain metastasis, median survival was 20 months (2-80 months) and in 71 patients with single brain metastasis it was 11 months (1-79 months) p = 0.01. Median survival from brain metastasis in patients with Recursive Partitioning Analysis Radiation Therapy Oncology Group (RPA RTOG) prognostic class I, II and III was 22 months (4-80 months), 13 months (2-79 months) and 6 months (0.4-28 months), respectively, p < 0.0001. Median survival from brain metastasis in triple-negative, HER2, luminal B and luminal A subtypes was 11 months, 13 months, 16 months and 15 months, respectively (p = 0.60). Multivariate analysis revealed that RPA RTOG prognostic class I, neurosurgery and systemic therapy after WBRT were factors that correlated with survival. CONCLUSIONS: In patients with one metastatic lesion in the brain, affiliation to RPA RTOG prognostic class I and intensive local and systemic treatment had a strong correlation with survival. There was no significant correlation between biological subtype of cancer and survival.
AIM: To perform a comprehensive analysis of patients with breast cancer and solitary or single brain metastasis and to analyze factors influencing survival from brain metastasis. METHODS: One hundred consecutive patients with single or solitary brain metastasis were treated in one institution in the years 2003-2009. Brain lesions were diagnosed by magnetic resonance imaging (MRI). A total of 57% of patients underwent resection of brain metastasis, 95% of patients received whole-brain radiation therapy (WBRT) and 67% were treated systemically after WBRT. RESULTS: Median survival from the detection of brain metastasis was 13 months and 28% of patients survived for 2 years. In 29 patients with solitary brain metastasis, median survival was 20 months (2-80 months) and in 71 patients with single brain metastasis it was 11 months (1-79 months) p = 0.01. Median survival from brain metastasis in patients with Recursive Partitioning Analysis Radiation Therapy Oncology Group (RPA RTOG) prognostic class I, II and III was 22 months (4-80 months), 13 months (2-79 months) and 6 months (0.4-28 months), respectively, p < 0.0001. Median survival from brain metastasis in triple-negative, HER2, luminal B and luminal A subtypes was 11 months, 13 months, 16 months and 15 months, respectively (p = 0.60). Multivariate analysis revealed that RPA RTOG prognostic class I, neurosurgery and systemic therapy after WBRT were factors that correlated with survival. CONCLUSIONS: In patients with one metastatic lesion in the brain, affiliation to RPA RTOG prognostic class I and intensive local and systemic treatment had a strong correlation with survival. There was no significant correlation between biological subtype of cancer and survival.
Authors: Kaisorn L Chaichana; Shami Acharya; Mariana Flores; Olindi Wijesekera; Daniele Rigamonti; Jon D Weingart; Alessandro Olivi; Chetan Bettegowda; Gary L Gallia; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa Journal: World Neurosurg Date: 2013-09-25 Impact factor: 2.104
Authors: Kaisorn L Chaichana; Shekhar Gadkaree; Karthik Rao; Thomas Link; Daniele Rigamonti; Michael Purtell; Ilene Browner; Jon Weingart; Alessandro Olivi; Gary Gallia; Chetan Bettegowda; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa Journal: Neurol Res Date: 2013-08-16 Impact factor: 2.448
Authors: José P Leone; Bernardo A Leone; Nabihah Tayob; Michael J Hassett; Julieta Leone; Rachel A Freedman; Sara M Tolaney; Eric P Winer; Carlos T Vallejo; Nancy U Lin Journal: Breast Cancer Res Treat Date: 2021-02-16 Impact factor: 4.872
Authors: Jawad Fares; Deepak Kanojia; Alex Cordero; Aida Rashidi; Jason Miska; Charles W Schwartz; Solomiia Savchuk; Atique U Ahmed; Irina V Balyasnikova; Massimo Cristofanilli; William J Gradishar; Maciej S Lesniak Journal: Neurooncol Pract Date: 2019-02-11
Authors: A Berghoff; Z Bago-Horvath; C De Vries; P Dubsky; U Pluschnig; M Rudas; A Rottenfusser; M Knauer; H Eiter; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger; M Preusser; R Bartsch Journal: Br J Cancer Date: 2012-01-10 Impact factor: 7.640
Authors: A S Berghoff; Z Bago-Horvath; A Ilhan-Mutlu; M Magerle; K Dieckmann; C Marosi; P Birner; G Widhalm; G G Steger; C C Zielinski; R Bartsch; M Preusser Journal: Br J Cancer Date: 2012-10-09 Impact factor: 7.640